Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1989 1
1990 4
1991 3
1992 4
1993 7
1994 4
1995 3
1996 4
1997 8
1998 6
1999 7
2000 7
2001 10
2002 9
2003 6
2004 13
2005 14
2006 9
2007 14
2008 9
2009 15
2010 14
2011 15
2012 20
2013 18
2014 15
2015 13
2016 21
2017 22
2018 23
2019 24
2020 20
2021 25
2022 28
2023 21
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

403 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pearls and promising therapies in myositis.
Connolly CM, Paik JJ. Connolly CM, et al. Expert Rev Clin Immunol. 2023 Jul-Dec;19(7):797-811. doi: 10.1080/1744666X.2023.2212162. Epub 2023 May 18. Expert Rev Clin Immunol. 2023. PMID: 37158055 Review.
However, advances utilizing myositis-specific autoantibodies have facilitated the definition of subgroups as well as the prediction of clinical phenotypes, disease course, and response to treatment. AREAS COVERED: Herein we provide an overview of the clinical presentations …
However, advances utilizing myositis-specific autoantibodies have facilitated the definition of subgroups as well as the prediction o …
Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O. Mariampillai K, et al. JAMA Neurol. 2018 Dec 1;75(12):1528-1537. doi: 10.1001/jamaneurol.2018.2598. JAMA Neurol. 2018. PMID: 30208379 Free PMC article.
Cluster 1 (n = 77) included patients who were male, white, and older than 60 years and had finger flexor and quadriceps weakness and findings of vacuolated fibers and mitochondrial abnormalities. Cluster 1 regrouped patients who had inclusion body myositis (7 …
Cluster 1 (n = 77) included patients who were male, white, and older than 60 years and had finger flexor and quadriceps weakness and finding …
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW. Rider LG, et al. Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11(0 11):S118-57. doi: 10.1002/acr.20532. Arthritis Care Res (Hoboken). 2011. PMID: 22588740 Free PMC article. Review. No abstract available.
Idiopathic inflammatory myositis.
Tieu J, Lundberg IE, Limaye V. Tieu J, et al. Best Pract Res Clin Rheumatol. 2016 Feb;30(1):149-68. doi: 10.1016/j.berh.2016.04.007. Epub 2016 May 26. Best Pract Res Clin Rheumatol. 2016. PMID: 27421222 Review.
In this paper, we outline key advances in diagnosis and histopathology, including the more recent identification of antibodies associated with immune-mediated necrotising myopathy (IMNM) and inclusion body myositis (IBM). Ongoing longitudinal observational …
In this paper, we outline key advances in diagnosis and histopathology, including the more recent identification of antibodies associated wi …
Current status of clinical outcome measures in inclusion body myositis: a systematised review.
Roy B, Lucchini M, Lilleker JB, Goyal NA, Naddaf E, Adler B, Alfano LN, Malandraki GA, Focht Garand KL, Mochel D, Badrising U, Machado PM, Pagkatipunan R, Ramdharry G, Wang L, Funaro MC, Schmidt J, Kushlaf H, Schiopu E, Stipancic K, Goyal N, d'Alessandro M, Conticini E, Cruz-Coble B, Lloyd TE; International Myositis Assessment and Clinical Studies (IMACS) Inclusion Body Myositis Scientific Interest Group. Roy B, et al. Clin Exp Rheumatol. 2023 Mar;41(2):370-378. doi: 10.55563/clinexprheumatol/ifacv3. Epub 2023 Feb 3. Clin Exp Rheumatol. 2023. PMID: 36762744 Free article. Review.
OBJECTIVES: Sporadic inclusion body myositis (IBM) is a debilitating idiopathic inflammatory myopathy (IIM) which affects hand function, ambulation, and swallowing. ...METHODS: In this systematised review, we have extracted all outcome measures reported in IB …
OBJECTIVES: Sporadic inclusion body myositis (IBM) is a debilitating idiopathic inflammatory myopathy (IIM) which affec …
Inclusion body myositis: update.
Lahouti AH, Amato AA, Christopher-Stine L. Lahouti AH, et al. Curr Opin Rheumatol. 2014 Nov;26(6):690-6. doi: 10.1097/BOR.0000000000000116. Curr Opin Rheumatol. 2014. PMID: 25215417 Review.
PURPOSE OF REVIEW: To examine new developments in sporadic inclusion body myositis (IBM), including updated clinical and prognostic factors, novel autoantibody associations, unique histopathologic findings, proposed new clinical diagnostic criteria, and novel …
PURPOSE OF REVIEW: To examine new developments in sporadic inclusion body myositis (IBM), including updated clinical an …
Muscle pathology of antisynthetase syndrome according to antibody subtypes.
Tanboon J, Inoue M, Hirakawa S, Tachimori H, Hayashi S, Noguchi S, Okiyama N, Fujimoto M, Suzuki S, Nishino I. Tanboon J, et al. Brain Pathol. 2023 Jul;33(4):e13155. doi: 10.1111/bpa.13155. Epub 2023 Mar 7. Brain Pathol. 2023. PMID: 36882048 Free PMC article. Review.
We used t-test and Fisher's exact for comparisons and used sensitivity, specificity, positive and negative predictive values to assess the utility of HLA-DR expression for ASS diagnosis. ...HLA-DR expression and IFN-gamma-related genes upregulation were prominent in ASS an …
We used t-test and Fisher's exact for comparisons and used sensitivity, specificity, positive and negative predictive values to asses …
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.
Machado PM, McDermott MP, Blaettler T, Sundgreen C, Amato AA, Ciafaloni E, Freimer M, Gibson SB, Jones SM, Levine TD, Lloyd TE, Mozaffar T, Shaibani AI, Wicklund M, Rosholm A, Carstensen TD, Bonefeld K, Jørgensen AN, Phonekeo K, Heim AJ, Herbelin L, Barohn RJ, Hanna MG, Dimachkie MM; Arimoclomol in IBM Investigator Team of the Neuromuscular Study Group. Machado PM, et al. Lancet Neurol. 2023 Oct;22(10):900-911. doi: 10.1016/S1474-4422(23)00275-2. Lancet Neurol. 2023. PMID: 37739573 Free article. Clinical Trial.
BACKGROUND: Inclusion body myositis is the most common progressive muscle wasting disease in people older than 50 years, with no effective drug treatment. ...Eligible participants had a diagnosis of inclusion body myositis fulfilling the …
BACKGROUND: Inclusion body myositis is the most common progressive muscle wasting disease in people older than 50 years …
Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings.
Pinto MV, Laughlin RS, Klein CJ, Mandrekar J, Naddaf E. Pinto MV, et al. Rheumatology (Oxford). 2022 May 30;61(6):2504-2511. doi: 10.1093/rheumatology/keab754. Rheumatology (Oxford). 2022. PMID: 34617994 Review.
OBJECTIVE: To determine whether histopathological, electromyographic and laboratory markers correlate with clinical measures in inclusion body myositis (IBM). METHODS: We reviewed our electronic medical records to identify patients with IBM according to Europ …
OBJECTIVE: To determine whether histopathological, electromyographic and laboratory markers correlate with clinical measures in inclusion …
C-terminal frameshift variant of TDP-43 with pronounced aggregation-propensity causes rimmed vacuole myopathy but not ALS/FTD.
Ervilha Pereira P, Schuermans N, Meylemans A, LeBlanc P, Versluys L, Copley KE, Rubien JD, Altheimer C, Peetermans M, Debackere E, Vanakker O, Janssens S, Baets J, Verhoeven K, Lammens M, Symoens S, De Paepe B, Barmada SJ, Shorter J, De Bleecker JL, Bogaert E, Dermaut B. Ervilha Pereira P, et al. Acta Neuropathol. 2023 Jun;145(6):793-814. doi: 10.1007/s00401-023-02565-1. Epub 2023 Mar 31. Acta Neuropathol. 2023. PMID: 37000196 Free PMC article.
TDP-43-positive inclusions are also found in rimmed vacuole myopathies, including sporadic inclusion body myositis, but myopathy-causing TDP-43 variants have not been reported. Using genome-wide linkage analysis and whole exome sequencing in an extended five- …
TDP-43-positive inclusions are also found in rimmed vacuole myopathies, including sporadic inclusion body myositis, but …
403 results